Lung Fluid Articles & Analysis: Older
9 news found
Hospitals treating COVID-19 patients are looking to use the radar-based technology, previously used in heart-failure patients, to monitor lungs of coronavirus patients. Sensible Medical has recently received urgent requests from hospitals around the world for its ReDS monitors systems to improve monitoring, treatment and resource use for COVID-19 patients. ...
ReDS™ Pro is used to measure the absolute lung fluid volume in patients, which has strong correlation with symptoms of Coronary Heart Failure (CHF). It is a non-invasive method that takes only 45 seconds to measure. Lung fluid assessment with ReDS™ Pro is proven to be as accurate as that measured by a CT scan. ...
Those patients are often in and out of hospitals because their lungs fill with fluid. But as CBS2’s Dr. Max Gomez reports, a new device – a “radar vest” – could prevent those hospital ...
Congestive heart failure is one of the most common reasons elderly people end up in the hospital. When this happens fluid builds up in the lungs and patients have trouble breathing. Cone Health is the first in the country to use a new technology to measure the amount of fluid in the lungs in the inpatient hospital setting. ...
Fluidda’s proprietary in silico platform FRI (Functional Respiratory Imaging) delivers quantitative predictions of regional drug deposition in disease state lungs using Computational Fluid Dynamics (CFD). The FRI platform provides critical information to help understand the availability and activity of the drug at the site of action in the ...
ByFluidda
Wearable devices such as remote dielectric sensing and adhesive patches allow for remote cardiac monitoring of lung fluid content, electrocardiograph, and physical activity, among others, but each has limitations and requires patients to make big changes that interrupt their daily lives. ...
“After IV delivery, the cells migrate to the lungs for local therapeutic benefit. We expect the anti-inflammatory nature of these mesenchymal stem cells to have a positive impact in ARDS because of the interaction of the Neurokinin-1 receptors with Substance P, a neuropeptide that has long been known to be a primary mediator of inflammation in the lungs. ...
The clinical trial will test the safety and maximum tolerable dose of LTI-01 in patients who have pneumonia-like symptoms with a build-up of non-draining fluid around their lungs. Lung Therapeutics has designed LTI-01 to treat empyema and Complicated Parapneumonic Effusions (CPE), two complications of pneumonia that can involve fibrinous scarring ...
Inhalation at low concentrations for a short period irritates the nose, throat, and lungs. Prolonged exposure or higher concentrations causes a burning sensation, coughing, gagging, chest pain, fluid in lungs, and possible suffocation and death. ...